

38. (Amended) A vaccine composition comprising as the active component a molecule capable of inducing an immune response directed to a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response directed to a lipidic domain of a GPI, together with one or more pharmaceutically acceptable carriers and/or diluents.

42. (Amended) A composition according to claim 37, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

43. (Amended) A composition according to claim 37, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

52. (Amended) A method of inhibiting, halting or delaying the onset or progression of a mammalian disease condition characterised by a micro-organism infection, said method comprising administering to said mammal an effective amount of an antibody as claimed in claim 50.

REMARKS

Applicant respectfully request that the foregoing amendments to Claims 4, 16, 26, 33, 42, 43 and 52 be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

VERSION WITH MARKINGS TO SHOW CHANGES MADE

4. (Amended) A method according to claim 2, [or 3] wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

16. (Amended) A method according to [any one of claims 13-15] claim 13, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

26. (Amended) A method according to claim 24 [or 25] claim 24, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

33. (Amended) A method according to [any one of claims 24-31] claim 24, wherein said disease condition is malaria.

38. (Amended) A vaccine composition comprising as the active component a molecule capable of inducing an immune response directed to a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response directed to a lipidic domain of a GPI, together with one or more pharmaceutically acceptable carriers and/or diluents.

42. (Amended) A composition according to [any one of claims 37, 39 or 41] claim 37 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

43. (Amended) A composition according to [any one or claims 37, 39, 41 or 42] claim 37 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

52. (Amended) A method of inhibiting, halting or delaying the onset or progression of a mammalian disease condition characterised by a micro-organism infection, said method comprising administering to said mammal an effective amount of an antibody as claimed in claim 50 [or 51].

Respectfully submitted,

Date March 14, 2001

By



FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768